Breaking News
Get 50% Off 0
Last Call 🚨 SAVE on InvestingPro
Get 50% Off
Close

Emyria Ltd (EMD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.05 0.00    -5.66%
07:04:59 - Closed. Currency in AUD
Type:  Equity
Market:  Australia
ISIN:  AU0000073645 
  • Volume: 7,333,449
  • Bid/Ask: 0.05 / 0.05
  • Day's Range: 0.05 - 0.06
Emyria 0.05 0.00 -5.66%

Emyria Ltd Company Profile

 
Get an in-depth profile of Emyria Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the advancement of Emyria’s MDMA analogue drug development program, targeting mental health and neurodegenerative diseases, including Parkinson’s. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Contact Information

Address D2, 661 Newcastle Street
Leederville, 6007
Australia
Phone 61 8 6559 2800
Fax 61 8 6559 2800

Top Executives

Name Age Since Title
David Putrino - - Member of Medical Advisory Board
Jennifer Morgan - - Member of Medical Advisory Board
Henry William Bosch - - Member of Medical Advisory Board
Mohit Kaushal 44 2023 Non-Executive Director
Nik Zeps - - Member of Medical Advisory Board
Philip Finch - - Member of Medical Advisory Board
Richard Magtengaard - 2021 Member of Medical Advisory Board
John Edward Tooke 74 2020 Member of Medical Advisory Board & Independent Non-Executive Director
Karen L. Smith 56 2021 Non-Executive Director & Chairman of Strategic Advisory Board
Michael Winlo - 2019 Chief Scientific Officer & Director
Alistair Vickery - 2019 Executive Medical Director & Director
Gregory Hutchinson - 2023 Executive Chairman
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EMD Comments

Write your thoughts about Emyria Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email